Literature DB >> 21327441

Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma.

Natsuko Tsuda Okita1, Ken Kato, Daisuke Takahari, Yoshinori Hirashima, Takako E Nakajima, Junichi Matsubara, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada, Hirokazu Taniguchi, Kuniaki Shirao.   

Abstract

BACKGROUND: Neuroendocrine tumors (NETs) occur in various primary sites, but rarely in the stomach. NETs are classified into three types, carcinoids, malignant carcinoids and poorly differentiated neuroendocrine carcinomas (PNECs), whose clinical behavior is different. Currently, clinical outcomes and standard chemotherapy for NETs of the stomach remain unclear.
METHODS: We conducted a retrospective review of histopathologically confirmed NETs of the stomach at our hospital between January 2000 and August 2006.
RESULTS: Thirty-seven NETs were identified. Fifteen patients had carcinoids while 22 had PNECs. Among the carcinoid patients, 7 underwent endoscopic mucosal resection and 5 had gastrectomy as first-line treatment. Three patients were observed without intervention. All patients were alive after an average follow-up period of 27 months. Among the 22 PNEC patients, 3 had no metastasis, 11 had regional lymph node metastasis, and 8 had distant metastasis. Eight of 14 patients relapsed at a median of 177 days (range 120-1459 days) after curative surgery. Twelve patients with metastatic or recurrent disease received palliative cisplatin plus irinotecan chemotherapy. The response rate was 75%, the median progression-free survival time was 212 days, and median survival time was 679 days.
CONCLUSION: Gastric PNEC patients with distant metastasis had poor outcomes. Regimens containing cisplatin plus irinotecan produced a good response in gastric PNEC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327441     DOI: 10.1007/s10120-011-0025-5

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  18 in total

1.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.

Authors:  A Aupérin; R Arriagada; J P Pignon; C Le Péchoux; A Gregor; R J Stephens; P E Kristjansen; B E Johnson; H Ueoka; H Wagner; J Aisner
Journal:  N Engl J Med       Date:  1999-08-12       Impact factor: 91.245

2.  A meta-analysis of thoracic radiotherapy for small-cell lung cancer.

Authors:  J P Pignon; R Arriagada; D C Ihde; D H Johnson; M C Perry; R L Souhami; O Brodin; R A Joss; M S Kies; B Lebeau
Journal:  N Engl J Med       Date:  1992-12-03       Impact factor: 91.245

Review 3.  Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options.

Authors:  R Arnold
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-08       Impact factor: 3.043

4.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

Authors:  Kazumasa Noda; Yutaka Nishiwaki; Masaaki Kawahara; Shunichi Negoro; Takahiko Sugiura; Akira Yokoyama; Masahiro Fukuoka; Kiyoshi Mori; Koshiro Watanabe; Tomohide Tamura; Seiichiro Yamamoto; Nagahiro Saijo
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

5.  Small cell carcinoma of the stomach: a clinicopathologic study of 17 cases.

Authors:  K Matsui; M Kitagawa; A Miwa; Y Kuroda; M Tsuji
Journal:  Am J Gastroenterol       Date:  1991-09       Impact factor: 10.864

6.  Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior.

Authors:  G Rindi; C Bordi; S Rappel; S La Rosa; M Stolte; E Solcia
Journal:  World J Surg       Date:  1996-02       Impact factor: 3.352

7.  A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.

Authors:  Matthew H Kulke; Bingyan Wu; David P Ryan; Peter C Enzinger; Andrew X Zhu; Jeffrey W Clark; Craig C Earle; Ann Michelini; Charles S Fuchs
Journal:  Dig Dis Sci       Date:  2006-06       Impact factor: 3.199

8.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

Review 9.  Gastric small-cell carcinoma in Japan: a case report and review of the literature.

Authors:  K Arai; M Matsuda
Journal:  Am J Clin Oncol       Date:  1998-10       Impact factor: 2.339

Review 10.  Small-cell carcinomas of the gastrointestinal tract: a review.

Authors:  Baruch Brenner; Laura H Tang; David S Klimstra; David P Kelsen
Journal:  J Clin Oncol       Date:  2004-07-01       Impact factor: 44.544

View more
  44 in total

Review 1.  Management of primary gastric small cell carcinoma in China.

Authors:  Qin-Qin Wu; Wei-Guang Qiang; Feng Wang; Ke-Jun Dai; En-Ci Xu; Ju-Dong Luo; Qing Li; Hua Tang; Xi-Fa Zhou; Xu-Jing Lu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum.

Authors:  James D Smith; Diane L Reidy; Karyn A Goodman; Jinru Shia; Garrett M Nash
Journal:  Ann Surg Oncol       Date:  2014-04-24       Impact factor: 5.344

Review 3.  Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.

Authors:  Ting-Ting Li; Feng Qiu; Zhi Rong Qian; Jun Wan; Xiao-Kun Qi; Ben-Yan Wu
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

4.  Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.

Authors:  Katharine E H Thomas; Brianne A Voros; J Philip Boudreaux; Ramcharan Thiagarajan; Eugene A Woltering; Robert A Ramirez
Journal:  Oncologist       Date:  2019-01-11

5.  Endocrine carcinoma of the stomach: clinicopathological analysis of 27 surgically treated cases in a single institute.

Authors:  Takeshi Kubota; Shigekazu Ohyama; Naoki Hiki; Souya Nunobe; Noriko Yamamoto; Toshiharu Yamaguchi
Journal:  Gastric Cancer       Date:  2012-01-18       Impact factor: 7.370

6.  Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas.

Authors:  Z H Lu; J Li; M Lu; X T Zhang; J Li; J Zhou; X C Wang; J F Gong; J Gao; Y Li; L Shen
Journal:  Med Oncol       Date:  2013-07-18       Impact factor: 3.064

7.  Neuroendocrine carcinoma of the stomach: A case report.

Authors:  Sang Hyun Kang; Kwang Hee Kim; Sang Hyuk Seo; Min Sung An; Tae Kwun Ha; Ha Kyung Park; Ki Beom Bae; Chang Soo Choi; Sang Hun Oh; Young Kil Choi
Journal:  World J Gastrointest Surg       Date:  2014-04-27

8.  Neuroendocrine carcinoma of the stomach: clinicopathological and immunohistochemical evaluation.

Authors:  Tsutomu Namikawa; Toyokazu Oki; Hiroyuki Kitagawa; Takehiro Okabayashi; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Med Mol Morphol       Date:  2013-01-10       Impact factor: 2.309

9.  Genetics and molecular pathology of gastric malignancy: Development of targeted therapies in the era of personalized medicine.

Authors:  Michael Van Ness; Jeffrey Gregg; Jun Wang; Mingyi Chen
Journal:  J Gastrointest Oncol       Date:  2012-09

Review 10.  Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma.

Authors:  Kazhan Mollazadegan; Staffan Welin; Joakim Crona
Journal:  Curr Treat Options Oncol       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.